EMEA-003063-PIP02-22 - paediatric investigation plan
Vibostolimab
Pembrolizumab
PIPHuman
Key facts
- Active Substance
- Vibostolimab
- Pembrolizumab
- Therapeutic area
- Oncology
- Decision number
- P/0174/2023
- PIP number
- EMEA-003063-PIP02-22
- Pharmaceutical form(s)
- Concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of Hodgkin lymphoma
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Merck Sharp & Dohme (Europe) Inc.
Tel.: +33180464738
E-mail: pip.information@merck.com- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)